Get the Stockscreener App
244.15
1.93%
-4.81
After Hours:
244.00
-0.15
-0.06%
Penumbra Inc stock is traded at $244.15, with a volume of 262.70K.
It is down -1.93% in the last 24 hours and up +19.27% over the past month.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
See More
Previous Close:
$248.96
Open:
$249.86
24h Volume:
262.70K
Relative Volume:
0.73
Market Cap:
$9.41B
Revenue:
$1.16B
Net Income/Loss:
$34.55M
P/E Ratio:
237.04
EPS:
1.03
Net Cash Flow:
$134.18M
1W Performance:
+2.07%
1M Performance:
+19.27%
6M Performance:
+26.07%
1Y Performance:
+5.68%
1-Day Range:
$240.30
$250.81
1-Week Range:
$235.93
$250.94
52-Week Range:
$148.00
$277.34
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
244.15 | 9.41B | 1.16B | 34.55M | 134.18M | 1.03 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Penumbra Inc (PEN) Stock Price Down 3.01% on Nov 27 - GuruFocus.com
Penumbra, Inc. (NYSE:PEN) Shares Sold by Algert Global LLC - MarketBeat
Leerink Partnrs Estimates Penumbra's Q4 Earnings (NYSE:PEN) - MarketBeat
Loomis Sayles & Co. L P Acquires 13,534 Shares of Penumbra, Inc. (NYSE:PEN) - MarketBeat
FY2024 EPS Estimates for Penumbra Raised by Leerink Partnrs - MarketBeat
Massachusetts Financial Services Co. MA Makes New $31.97 Million Investment in Penumbra, Inc. (NYSE:PEN) - MarketBeat
Penumbra, Inc. (PEN): Innovating in Thrombectomy and Embolization with New FDA-Approved Technologies - Insider Monkey
PEN (Penumbra) Total Assets : $1,479 Mil (As of Sep. 2024) - GuruFocus.com
PEN (Penumbra) Cyclically Adjusted PB Ratio : 12.96 (As of Nov. 25, 2024) - GuruFocus.com
Penumbra, Inc. (NYSE:PEN) Stock Position Lowered by Intech Investment Management LLC - MarketBeat
Natixis Advisors LLC Has $5.39 Million Position in Penumbra, Inc. (NYSE:PEN) - MarketBeat
Penumbra, Inc. (NYSE:PEN) CEO Adam Elsesser Sells 15,000 Shares - MarketBeat
3 Reasons Growth Investors Will Love Penumbra (PEN) - Yahoo Finance
Penumbra to Present at Piper Sandler Healthcare Conference in December 2024 | PEN Stock News - StockTitan
Penumbra price target raised to $250 from $235 at Piper Sandler - TipRanks
Breaking Down Penumbra: 11 Analysts Share Their Views - Benzinga
Penumbra Secures Innovation Award for Breakthrough Thrombectomy Technologies - Medical Device Network
When the Price of (PEN) Talks, People Listen - Stock Traders Daily
LMR Partners LLP Makes New $2.33 Million Investment in Penumbra, Inc. (NYSE:PEN) - MarketBeat
Penumbra, Inc. (NYSE:PEN) Holdings Lifted by Thrivent Financial for Lutherans - MarketBeat
Penumbra, Inc. (PEN): A Bull Case Theory - Insider Monkey
Principal Financial Group Inc. Decreases Stock Holdings in Penumbra, Inc. (NYSE:PEN) - MarketBeat
Los Angeles Capital Management LLC Acquires 8,222 Shares of Penumbra, Inc. (NYSE:PEN) - MarketBeat
Baillie Gifford & Co. Has $115 Million Stock Position in Penumbra, Inc. (NYSE:PEN) - MarketBeat
SpiderRock Advisors LLC Purchases Shares of 2,645 Penumbra, Inc. (NYSE:PEN) - MarketBeat
Immersive VR Market Analysis 2024-2029 with Meta, Sony, - GlobeNewswire
Analysts Set Penumbra, Inc. (NYSE:PEN) Price Target at $226.67 - MarketBeat
There May Be Some Bright Spots In Penumbra's (NYSE:PEN) Earnings - Yahoo Finance
Intracranial Stents Market Expected to Reach US$ 702.8 Million - openPR
Penumbra reveals positive data for algorithm-assisted thrombectomy tech - Clinical Trials Arena
Here's Why Penumbra (PEN) is a Strong Momentum Stock - MSN
Here is Why Growth Investors Should Buy Penumbra (PEN) Now - Yahoo Finance
Penumbra has positive data for computer-assisted vacuum thrombectomy system - Mass Device
Penumbra reports shorter stays, fewer PE complications with CAVT - Investing.com
Penumbra reports shorter stays, fewer PE complications with CAVT By Investing.com - Investing.com Canada
Penumbra's CAVT Tech Shows 35% Shorter Hospital Stays, 3x Fewer PE Complications | PEN Stock News - StockTitan
AlphaCentric Advisors LLC Buys New Stake in Penumbra, Inc. (NYSE:PEN) - MarketBeat
Penumbra's SWOT analysis: innovation drives growth amid market challenges - Investing.com India
Penumbra shares rise as Canaccord lifts target, keeps at Buy list - Investing.com Canada
Implied Volatility Surging for Penumbra (PEN) Stock Options - MSN
Penumbra revenue jumps 11.1% to USD 301M in Q3 2024 - Medical Buyer
William Blair Weighs in on Penumbra's Q1 Earnings (NYSE:PEN) - MarketBeat
Penumbra, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year - Yahoo Finance
Is Penumbra, Inc.'s (NYSE:PEN) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Simply Wall St
Penumbra Inc (PEN) Shares Up 3.26% on Nov 1 - GuruFocus.com
Penumbra Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Leerink Partnrs Has Bearish Outlook for Penumbra Q4 Earnings - MarketBeat
Penumbra, Inc. (NYSE:PEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Exploring the Future of Virtual Reality: Market Overview, Trends, Analysis & Key Players - GlobeNewswire Inc.
Penumbra stock maintains buy rating with BTIG despite price target cut - Investing.com India
Penumbra Inc (PEN) Trading 4.48% Higher on Oct 31 - GuruFocus.com
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):